Patents by Inventor Takashi Ohkura

Takashi Ohkura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10539576
    Abstract: An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: January 21, 2020
    Assignees: National Institute of Advanced Industrial Science and Technology, Tokyo Medical University
    Inventors: Hisashi Narimatsu, Akira Togayachi, Yuzuru Ikehara, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Hideki Matsuzaki, Yoshitoshi Hirao, Jun Iwaki, Minako Abe, Masaharu Nomura, Masayuki Noguchi
  • Patent number: 9796761
    Abstract: The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: October 24, 2017
    Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE, GLYCOBIOMARKER LEADING INNOVATION CO., LTD.
    Inventors: Hisashi Narimatsu, Jun Hirabayashi, Yuzuru Ikehara, Takashi Angata, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Toshihide Shikanai, Maki Sogabe, Akira Togayachi, Makoto Ochou, Yasuhito Tanaka, Masashi Mizokami
  • Publication number: 20170283506
    Abstract: An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
    Type: Application
    Filed: June 12, 2017
    Publication date: October 5, 2017
    Applicants: National Institute of Advanced Industrial Science and Technology, Tokyo Medical University
    Inventors: Hisashi Narimatsu, Akira Togayachi, Yuzuru Ikehara, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Hideki Matsuzaki, Yoshitoshi Hirao, Jun Iwaki, Minako Abe, Masaharu Nomura, Masayuki Noguchi
  • Patent number: 9696320
    Abstract: An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: July 4, 2017
    Assignees: National Institute of Advanced Industrial Science and Technology, Tokyo Medical University
    Inventors: Hisashi Narimatsu, Akira Togayachi, Yuzuru Ikehara, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Hideki Matsuzaki, Yoshitoshi Hirao, Jun Iwaki, Minako Abe, Masaharu Nomura, Masayuki Noguchi
  • Publication number: 20150293104
    Abstract: An object of the present invention is to develop and provide an epithelial ovarian cancer diagnosis marker with which epithelial ovarian cancer can be detected inexpensively, conveniently, and low invasively with high accuracy, and a method for determining the presence or absence of epithelial ovarian cancer using the marker. The present invention provides a glycoprotein having a glycan-linked asparagine residue at a particular site of the glycoprotein secreted from an epithelial ovarian cancer cell, or a fragment thereof having the glycan as an epithelial ovarian cancer diagnosis marker. The present invention also provides a method for determining the presence or absence of epithelial ovarian cancer using the glycoprotein.
    Type: Application
    Filed: July 12, 2012
    Publication date: October 15, 2015
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Hirofumi Nozaki, Takashi Ohkura, Atsushi Kuno, Maki Sogabe, Tomomi Kubota, Hiroyuki Kaji, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hayao Nakanishi, Toru Nakanishi
  • Publication number: 20130288272
    Abstract: An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
    Type: Application
    Filed: September 9, 2011
    Publication date: October 31, 2013
    Applicants: TOKYO MEDICAL UNIVERSITY, NATIONAL INSTIUTE OF ADVANCED INDUSTRIAL SCIENCE A
    Inventors: Hisashi Narimatsu, Akira Togayachi, Yuzuru Ikehara, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Hideki Matsuzaki, Yoshitoshi Hirao, Jun Iwaki, Minako Abe, Masaharu Nomura, Masayuki Noguchi
  • Publication number: 20120190576
    Abstract: The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.
    Type: Application
    Filed: July 12, 2010
    Publication date: July 26, 2012
    Inventors: Hisashi Narimatsu, Jun Hirabayashi, Yuzuru Ikehara, Takashi Angata, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Toshihide Shikanai, Maki Sogabe, Akira Togayachi, Makoto Ochou, Yasuhito Tanaka, Masashi Mizokami